SCHEMBL14974248

SCHEMBL14974248

CCC(=Cc1cnc(-c2ccc(OCc3ccccc3)c(C34CC5CC(CC(C5)C3)C4)c2)nc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 4/20 0.43
XDH P47989 1/20 0.41
IKBKB O14920 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
RARA P10276 5/20 0.41
RARB P10826 4/20 0.41
RARG P13631 4/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NR1I2 O75469 1/20 0.41
PGR P06401 1/20 0.41
HSPD1 P10809 1/20 0.41
GOT1 P17174 1/20 0.41
GLRA1 P23415 1/20 0.41
BLM P54132 1/20 0.41
HSPE1 P61604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391032 0.89 HDAC11 (0.46) HDAC11IKBKBSMN1; SMN2NPC1HPGD
SCHEMBL14974229 0.87 HDAC11 (0.40) HDAC11IKBKBSMN1; SMN2NPC1HPGD
SCHEMBL2393669 0.87 HDAC11 (0.42) HDAC11IKBKBSMN1; SMN2NPC1HPGD
SCHEMBL2394235 0.86 HDAC11 (0.42) HDAC11SMN1; SMN2NPC1HPGDRAB9A
SCHEMBL2387859 0.86 LMNA (0.45) HDAC11SMN1; SMN2NPC1HPGDRAB9A
SCHEMBL2391373 0.85 HDAC11 (0.43) HDAC11IKBKBRARARARBRARG
SCHEMBL2390068 0.85 HDAC11 (0.43) HDAC11IKBKBRARARARBRARG
SCHEMBL2394296 0.85 HDAC11 (0.45) HDAC11IKBKBSMN1; SMN2NPC1HPGD
SCHEMBL2390729 0.85 HDAC11 (0.44) HDAC11IKBKBSMN1; SMN2RAB9ARARA
SCHEMBL2395834 0.85 PTPN11 (0.48) HDAC11RARARARBRARGLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096544-B2 Therapeutic compounds WAYNE STATE UNIVERSITY (US) 2015-08-04 US disclosed
US-20130137699-A1 THERAPEUTIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137699-A1 THERAPEUTIC COMPOUNDS BAX, MCL1, TMBIM6 HDAC11 294/4885XDH 2190/4885IKBKB 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.